SCHEMBL20524059

SCHEMBL20524059

O=C(NCCc1cc(C(=O)NO)no1)c1ccc(Cl)cc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 10/20 0.78
HDAC1 Q13547 6/20 0.78
HDAC4 P56524 2/20 0.78
HDAC7 Q8WUI4 2/20 0.78
HDAC11 Q96DB2 2/20 0.78
HDAC8 Q9BY41 2/20 0.78
HDAC9 Q9UKV0 2/20 0.78
HDAC5 Q9UQL6 2/20 0.78
LMNA P02545 1/20 0.52
NPC1 O15118 3/20 0.49
RAB9A P51151 3/20 0.49
TAAR1 Q96RJ0 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CYP1A2 P05177 2/20 0.49
GAA P10253 1/20 0.49
CYP2D6 P10635 1/20 0.49
MAPT P10636 1/20 0.49
CYP2C19 P33261 1/20 0.49
GFER P55789 1/20 0.49
TSHR P16473 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20524034 0.88 HDAC6 (0.79) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL29629616 0.88 HDAC6 (1.00) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524113 0.88 HDAC6 (1.00) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524097 0.87 HDAC6 (0.77) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL24754409 0.87 HDAC6 (0.77) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL29629621 0.87 HDAC6 (0.81) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524146 0.87 HDAC6 (0.81) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524111 0.87 HDAC6 (1.00) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524046 0.85 HDAC6 (0.83) HDAC6HDAC1HDAC4HDAC7HDAC11
SCHEMBL20524122 0.85 HDAC6 (0.73) HDAC6HDAC1HDAC4HDAC7HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US claimed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US claimed
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-07-02 US claimed
US-11472780-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY (US) 2022-10-18 US claimed
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2022-05-19 US claimed
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION 2020-04-16 US claimed
EP-3600295-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS The George Washington University, A Congressionally Chartered Not-For-Profit Corporation (US) 2020-02-05 EP claimed
WO-2018183701-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY (US) 2018-10-04 WO claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US disclosed
US-12522572-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-01-13 US disclosed
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-10-17 US disclosed
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-07-02 US disclosed
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2024-07-02 US disclosed
US-11472780-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors THE GEORGE WASHINGTON UNIVERSITY (US) 2022-10-18 US disclosed
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2022-05-19 US disclosed
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2022-05-19 US disclosed
WO-2022094319-A1 STAT-ACTIVATED MACROPHAGES, COMPOSITIONS, AND USES THEREOF THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2022-05-05 WO disclosed
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION 2020-04-16 US disclosed
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION 2020-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC3, HDAC1, HDAC4 HDAC6 10/4885HDAC1 2/4885HDAC4 3/4885
US-20220153709-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885
US-11472780-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885
US-12024493-B2 Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885
US-20240343697-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885
US-20200115350-A1 Isoxazole Hydroxamic Acids As Histone Deacetylase 6 Inhibitors HDAC1, HDAC7, HDAC5 HDAC6 10/4885HDAC1 1/4885HDAC4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.